CAS 936563-87-0

Ibrutinib Racemate

CAS : 936563-87-0

Ibrutinib is an inhibitor of tyrosine kinases, including BTK, ABL1, and PDGFR. It is a racemic mixture of ibrutinib enantiomers that has been shown to be effective against lymphocytic leukemia. Ibrutinib has minimal toxicity in humans and has been shown to be well-tolerated with few side effects. Ibrutinib binds to the active site of BTK, blocking the attachment of ATP and leading to inhibition of downstream signaling pathways that are involved in cell proliferation and survival. The drug also inhibits the activity of other tyrosine kinases such as ABL1 and PDGFR.

Formule : C₂₅H₂₄N₆O₂

Degré de pureté : Min. 95%

Masse moléculaire : 440.5 g/mol

Ref: 3D-LMB56387

Ibrutinib Racemate

CAS : 936563-87-0

Formule : C₂₅H₂₄N₆O₂

Masse moléculaire : 440.51

Ref: ST-EA-CP-I20048

Ibrutinib Racemate

CAS : 936563-87-0

Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.

Formule : C₂₅H₂₄N₆O₂

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 440.5

Ref: TM-T16440